Cite

    Luciani, M. et al. (2018). Phase 3, single‐arm, multicenter study of dabigatran etexilate for secondary prevention of venous thromboembolism in children: Rationale and design. Research and practice in thrombosis and haemostasis. 2 (3), pp. 580-590. [Online].